Skip to main content

Orchid Cellmark to Buy DNA-Testing Shop Reliagene for $8.6M in Cash and Stock

NEW YORK (GenomeWeb News) — Orchid Cellmark said yesterday it plans to buy Reliagene Technologies, a forensic and paternity DNA-analysis company, for $5.6 million in cash and $3 million in Orchid Cellmark restricted common stock.
 
Reliagene, which earned $7.5 million in revenue in 2006, “fits the criteria we are seeking in accelerating the growth of our business through acquisitions,” Orchid CEO Thomas Bologna said in a statement.
 
He said there is “essentially no customer overlap” between the two companies, and “the combined forensic casework, CODIS, and paternity laboratory testing volumes should increase our operational efficiencies.”
 
Bologna added that Orchid expects the acquisition to begin to be accretive in the second half of 2008.
 
Financial details were not disclosed, but Orchid said the selling price may change based on Reliagene’s working capital, and part of its payment will be held in escrow until “certain conditions, including the seller’s indemnification obligations,” are met.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.